Compare TG Therapeutics Inc (TGTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TotalEnergies SE — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while TotalEnergies SE trades at $86.9 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 25.7× TG Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TTE | |
|---|---|---|
Market Cap | $7.64B | $196.06B |
Sector | Health | Energy |
52-Week High | $59.06 | $93.60 |
52-Week Low | $26.94 | $57.39 |
Enterprise Value | $7.84B | $227.06B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
TotalEnergies (TTE) trades at $87.46, down 0.57% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed quarterly beats, while revenue declined to $182.34B in 2025. The company is expanding in renewables, acquiring Shell's European onshore renewables business and partnering on a Cyprus gas field development.
TTE offers value with a P/E of 11.01 and a 57.58% buy rating from analysts, targeting $94.00. Risks include declining revenue trends, legal challenges from climate litigation, and oil price volatility. The stock presents a balanced opportunity with income from dividends but faces execution risks in energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
